Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA’s Royalty Portfolio Expands Significantly

Aug 12, 2019 7:30am EDT

XOMA Reports Second Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

Aug 06, 2019 7:30am EDT

XOMA to Present at the 2019 Wedbush PacGrow Healthcare Conference

Jul 30, 2019 6:30am EDT

First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma

Jun 13, 2019 6:45am EDT

XOMA Reports First Quarter 2019 Financial Results and Operating Highlights

May 06, 2019 4:30pm EDT

XOMA Acquires Royalty Rights to Five Hematology Candidates

Apr 08, 2019 6:00am EDT

XOMA to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

Apr 03, 2019 7:00am EDT

XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights

Mar 07, 2019 7:05am EST

XOMA to Present at the Cowen and Company 39th Annual Health Care Conference

Mar 05, 2019 7:00am EST

XOMA Receives $5.5 Million Payment from Rezolute

Feb 13, 2019 7:00am EST
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...43
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2023 XOMA Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2023 XOMA • Powered by GeneratePress
    Scroll back to top